

## Cost-effectiveness of one-stop-shop [<sup>18</sup>F]Fluorocholine PET/CT to localise parathyroid adenomas in patients suffering from primary hyperparathyroidism

van Mossel, Sietse; Saing, Sopany; Appelman-Dijkstra, Natasha; Quak, Elske; Schepers, Abbey; Smit, Frits; de Geus-Oei, Lioe Fee; Vriens, Dennis

**DOI**

[10.1007/s00259-024-06771-1](https://doi.org/10.1007/s00259-024-06771-1)

**Publication date**

2024

**Document Version**

Final published version

**Published in**

European Journal of Nuclear Medicine and Molecular Imaging

**Citation (APA)**

van Mossel, S., Saing, S., Appelman-Dijkstra, N., Quak, E., Schepers, A., Smit, F., de Geus-Oei, L. F., & Vriens, D. (2024). Cost-effectiveness of one-stop-shop [<sup>18</sup>F]Fluorocholine PET/CT to localise parathyroid adenomas in patients suffering from primary hyperparathyroidism. *European Journal of Nuclear Medicine and Molecular Imaging*, 51(12), 3585-3595. <https://doi.org/10.1007/s00259-024-06771-1>

**Important note**

To cite this publication, please use the final published version (if applicable).  
Please check the document version above.

**Copyright**

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

**Takedown policy**

Please contact us and provide details if you believe this document breaches copyrights.  
We will remove access to the work immediately and investigate your claim.



# Cost-effectiveness of one-stop-shop [<sup>18</sup>F]Fluorocholine PET/CT to localise parathyroid adenomas in patients suffering from primary hyperparathyroidism

Sietse van Mossel<sup>1,2</sup> · Sopany Saing<sup>3</sup> · Natasha Appelman-Dijkstra<sup>4,5</sup> · Elske Quak<sup>6</sup> · Abbey Schepers<sup>7</sup> · Frits Smit<sup>1,8</sup> · Lioe-Fee de Geus-Oei<sup>1,2,9</sup> · Dennis Vriens<sup>1,5,10</sup>

Received: 15 February 2024 / Accepted: 11 May 2024

© The Author(s) 2024

## Abstract

**Purpose** We conducted a cost-effectiveness analysis in which we compared a preoperative [<sup>18</sup>F]Fluorocholine PET/CT-based one-stop-shop imaging strategy with current best practice in which [<sup>18</sup>F]Fluorocholine PET/CT is only recommended after negative or inconclusive [<sup>99m</sup>Tc]Tc-methoxy isobutyl isonitrile SPECT/CT for patients suffering from primary hyperparathyroidism. We investigated whether the one-stop-shop strategy performs as well as current best practice but at lower costs.

**Methods** We developed a cohort-level state transition model to evaluate both imaging strategies respecting an intraoperative parathyroid hormone monitored treatment setting as well as a traditional treatment setting. The model reflects patients' hospital journeys after biochemically diagnosed primary hyperparathyroidism. A cycle length of twelve months and a lifetime horizon were used. We conducted probabilistic analyses simulating 50,000 cohorts to assess joint parameter uncertainty. The incremental net monetary benefit and cost for each quality-adjusted life year were estimated. Furthermore, threshold analyses regarding the tariff of [<sup>18</sup>F]Fluorocholine PET/CT and the sensitivity of [<sup>99m</sup>Tc]Tc-methoxy isobutyl isonitrile SPECT/CT were performed.

**Results** The simulated long-term health effects and costs were similar for both imaging strategies. Accordingly, there was no incremental net monetary benefit and the one-stop-shop strategy did not result in lower costs. These results applied to both treatment settings. The threshold analysis indicated that a tariff of €885 for [<sup>18</sup>F]Fluorocholine PET/CT was required to be cost-effective compared to current best practice.

**Conclusion** Both preoperative imaging strategies can be used interchangeably. Daily clinical practice grounds such as available local resources and patient preferences should inform policy-making on whether a hospital should implement the one-stop-shop imaging strategy.

**Keywords** Hyperparathyroidism · Parathyroid · PET/CT · Cost-effectiveness · Fluorocholine · Sestamibi

✉ Sietse van Mossel  
s.vanmossel-1@utwente.nl

<sup>1</sup> Department of Radiology, Section Nuclear Medicine, Leiden University Medical Centre, Leiden, The Netherlands

<sup>2</sup> Biomedical Photonic Imaging, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands

<sup>3</sup> Faculty of Behavioural Management and Social Sciences, Health Technology and Services Research, University of Twente, Enschede, The Netherlands

<sup>4</sup> Department of Internal Medicine, Division Endocrinology, Leiden University Medical Centre, Leiden, The Netherlands

<sup>5</sup> Centre for Bone Quality Leiden, Leiden University Medical Centre, Leiden, The Netherlands

<sup>6</sup> Department of Nuclear Medicine, Centre François Baclesse, Caen, France

<sup>7</sup> Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands

<sup>8</sup> Department of Radiology, Section Nuclear Medicine, Alrijne Medical Centre, Leiden, The Netherlands

<sup>9</sup> Department of Radiation Sciences and Technology, Delft University of Technology, Delft, The Netherlands

<sup>10</sup> Department of Medical Imaging, Radboud University Medical Centre, Nijmegen, The Netherlands

## Introduction

Primary hyperparathyroidism (PHPT) is an endocrine disorder characterised by the parathyroid glands' autonomous secretion of parathyroid hormone (PTH). This is caused by a solitary parathyroid adenoma in 85% of cases, by parathyroid hyperplasia in 10% of cases, by multiple adenomas in 5% of cases and by parathyroid carcinoma in less than 1% of cases [1–4]. PHPT may result in neurological symptoms, renal events and osteoporosis with or without fractures [5, 6], causing increased morbidity and decreased quality of life (QoL) [7, 8].

The hallmark of diagnosing PHPT is biochemical testing indicating an inappropriate PTH response with respect to the serum calcium level. Imaging is used to localise the enlarged parathyroids and to determine the optimal surgical approach. In current best practice guidelines, a combination of morphological and molecular imaging is recommended consisting of cervical ultrasonography (US) and parathyroid scintigraphy with 2-phase single-photon emission computed tomography and computed tomography (SPECT/CT) using [ $^{99m}\text{Tc}$ ]Tc-methoxy isobutyl isonitrile (MIBI) as radiopharmaceutical [9, 10]. Currently, partial-body [ $^{18}\text{F}$ ]Fluorocholine ([ $^{18}\text{F}$ ]FCH) positron emission tomography and computed tomography (PET/CT) is only recommended after negative or inconclusive MIBI SPECT/CT [11–13]. Partial-body [ $^{18}\text{F}$ ]FCH PET/CT, however, might substitute conventional imaging including US and MIBI SPECT/CT [14–16], such that imaging can be developed into an [ $^{18}\text{F}$ ]FCH PET/CT-based one-stop-shop localisation strategy [17, 18]. In line with this, a recent network meta-analysis including a total of 8,495 patients from 119 direct competitive studies demonstrated the superior performance of [ $^{18}\text{F}$ ]FCH PET/CT in both patient-based and lesion-based analyses [19].

PHPT can only be cured with surgery. In case of localised single parathyroid adenoma, minimally invasive parathyroidectomy (MIP) can be performed. Otherwise, an explorative neck dissection can be performed in which all parathyroid glands are visually inspected [20–24]. To minimise the risk of persistent or recurrent hyperparathyroidism, rapid intraoperative PTH (ioPTH) monitoring can prevent a secondary neck exploration at the cost of longer durations of surgery and challenging logistics [25, 26]. MIP is associated with decreased complication rates while maintaining high cure and low recurrence rates compared to a neck exploration [27–32]. MIP also decreases the risk of hypoparathyroidism and postinterventional hospital visits [33, 34], both associated with decreased QoL [35, 36]. However, the move towards MIP highly depends on the preoperative imaging strategy used. Therefore, it is essential to evaluate the impact of imaging on long-term health

effects and costs as [ $^{18}\text{F}$ ]FCH PET/CT is currently more expensive than MIBI SPECT/CT.

We conducted a model-based cost-effectiveness analysis in which we compared the [ $^{18}\text{F}$ ]FCH PET/CT one-stop-shop strategy to current best practice in which [ $^{18}\text{F}$ ]FCH PET/CT is only recommended after negative or inconclusive MIBI SPECT/CT. We studied whether the one-stop-shop strategy performs as well as current best practice but at a lower cost. This article aims to provide recommendations for the optimal imaging strategy to localise parathyroid adenomas when costs are taken into consideration.

## Material and methods


This study was exempt from approval by the local ethics committee as it did not include individual patient data. Instead, all model parameters were obtained from literature evidence or were elicited from an expert panel. Clinical evidence was mainly based on publications from the European Endocrine Surgical Quality Registry (EUROCRINE) including parathyroid diseases [37]. A hospital perspective was adopted in which health-related utilities and direct health-care costs were covered. For all simulation analyses, R Statistical Software (version 4.2.1) was used [38], with software packages ‘dampack’ and ‘darthtools’ [39, 40]. This study is reported following the Consolidated Health Economic Evaluation Reporting Standards (Online Resource 1) [41].

### Imaging strategies

In this study, current best practice is compared with the [ $^{18}\text{F}$ ]FCH PET/CT-based one-stop-shop imaging strategy. In current best practice, [ $^{18}\text{F}$ ]FCH PET/CT is only provided after negative or inconclusive US and MIBI SPECT/CT (Fig. 1a) [9, 10]. In the one-stop-shop strategy, conventional imaging including US and MIBI SPECT/CT will no longer be provided (Fig. 1b) [17, 18]. As described in the 2021 European Association of Nuclear Medicine practice guidelines for parathyroid imaging, preoperative US provides an additional evaluation of the thyroid that might change patient management, especially in the case of coexisting (suspected) malignant nodules [9]. Therefore, in a separate simulation, we slightly adjusted the one-stop-shop strategy by including preoperative US.

### Treatment settings

We developed a cohort-level state transition model (cSTM) to evaluate the long-term health effects and costs of current best practice compared to the one-stop-shop imaging strategy. Current best practice and the one-stop-shop strategy were both covered in two different treatment settings.




**Fig. 1** Imaging strategies are visualised. The figure shows (a) current best practice [9, 10] compared to (b) the one-stop-shop strategy [17, 18]. In current best practice, [<sup>18</sup>F]FCH PET/CT is only provided after negative or inconclusive MIBI SPECT/CT. In the one-stop-shop strategy, conventional imaging including US and MIBI SPECT/CT

is no longer provided. Abbreviations: PHPT, primary hyperparathyroidism. US, ultrasonography. MIBI SPECT/CT, single-photon emission computed tomography and computed tomography using [<sup>99m</sup>Tc] Tc-methoxy isobutyl isonitrile. [<sup>18</sup>F]FCH PET/CT, positron emission tomography and computed tomography using [<sup>18</sup>F]Fluorocholine

Both treatment settings are representative of daily clinical practice. The first treatment setting consists of MIP with ioPTH monitoring in case of positive imaging results and explorative neck dissection with ioPTH monitoring in case of negative or inconclusive imaging results, referred to as the ioPTH-monitored treatment setting (Fig. 2a). In this setting, MIP might be directly converted to explorative neck dissection based on ioPTH monitoring. The second treatment setting consists of MIP without ioPTH monitoring in case of positive imaging results and pharmacotherapy in case of negative or inconclusive imaging results, referred to as the traditional treatment setting (Fig. 2b). An expert panel consisting of two medical imaging specialists (LFG-O and DV), one endocrinologist specialised in bone and mineral diseases (NMA-D) and one surgeon specialised in endocrine neck surgery (AS), all involved in the daily care of PHPT patients, was routinely consulted to discuss the imaging strategies (Fig. 1) and corresponding treatment settings (Fig. 2).

### State-transition modelling

The cSTM reflects patients' hospital journeys after biochemically diagnosed and localised PHPT. Separate entry points were defined for patients with positive and negative or inconclusive imaging results (Online Resource 2). Depending on the imaging result and treatment setting, patients receive MIP, explorative neck dissection, pharmacotherapy or active surveillance. MIP might be immediately converted to explorative neck dissection based on ioPTH monitoring (if accessible). Subsequently, patients are either cured, suffer from persistent hypoparathyroidism or suffer from persistent hyperparathyroidism. In case of the latter, patients have a yearly probability to receive repeat [<sup>18</sup>F]FCH PET/CT scans of which a subgroup will receive secondary parathyroidectomy. Otherwise, patients experience persistent hyperparathyroidism treated pharmacologically or symptomatically including active management of serum calcium concentrations and bone density with routine vitamin D



**Fig. 2** Treatment settings are visualised. The figure shows **(a)** the ioPTH-monitored treatment setting and **(b)** the traditional treatment setting. In both settings, five health states (ovals), several transition probabilities after each 12-month cycle length (arrows) and multiple lines of imaging and treatments (boxes) that patients may receive during their hospital journey are included. Patients enter the model when receiving a positive or negative/inconclusive imaging result.

supplementation and medication such as bisphosphonates, denosumab or calcimimetics. A subgroup of these patients will develop secondary disorders including neurological, cardiovascular, bone and renal events causing increased morbidity and decreased QoL.

### Model parameters

The simulated cohorts had a mean age of 62 years at baseline reflecting the mean age of patients diagnosed with

MIP might be directly converted to explorative neck dissection based on ioPTH monitoring. Secondary disorders include neurological, cardiovascular, bone and renal events causing increased morbidity and decreased QoL. Abbreviations: ioPTH, intraoperative parathyroid hormone serum level. MIP, minimally invasive parathyroidectomy. QoL, quality of life

PHPT [25]. A fixed cycle length of twelve months and a lifetime simulation horizon were used. Iteratively, we simulated 50,000 cohorts. The cSTM covered a large set of input parameters such as imaging characteristics, transition probabilities, relative risks, cure and mortality rates (Online Resource 3). An important parameter was the utilisation of the [ $^{18}\text{F}$ ]FCH PET/CT scanner in current best practice. The utilisation level directly depended on the estimated probability of negative or inconclusive conventional imaging (base case value of 20.4% of all patients [25]). Other important

parameters covered the conditional probabilities of full curation after targeted and explorative parathyroidectomy (pooled base case value of 95.7% of all patients [25]) and the conditional probabilities of experiencing neurological, cardiovascular, bone or renal events in case of no curation (pooled base case value of 24.6% of all non-curative patients [5, 6]). It is also worth noting that the base case probability of immediate conversion of MIP to explorative neck dissection was 8.5% in the ioPTH-monitored treatment setting [25]. The simulated transition probabilities and relative risks were dependent on the time since the start of the simulation and the time spent in a health state. The simulation time dependency captured the increasing age-dependent background mortality and the state-residence time dependency captured the time spent in a given health state. The age-dependent background mortality rates were retrieved from Dutch demographic data for the period 2018–2022 from Statistics Netherlands [42].

### Cost information

Cost data were gathered from a healthcare perspective covering the costs related to diagnostics, medication and treatments (Online Resource 3). These costs were approximated by utilising the Dutch healthcare authority tariffs 2023 covered in the Dutch system of diagnosis treatment combinations [43] and drug database [44], accompanied by the Leiden University Medical Center specific reference tariffs. The model used a base case tariff of €965 for partial-body [<sup>18</sup>F]FCH PET/CT, a base case tariff of €237 for planar parathyroid scintigraphy, a base case tariff of €350 for thorax-neck MIBI SPECT/CT and a base case tariff of €84 for cervical US. The costs of treatment-related complications were reflected by covering the costs of prolonged hospitalisation and additional interventions required. According to the Dutch guidelines, an annual discount rate of 3% was applied to all future costs [45].

### Health effects

Utilities and disutilities based on EQ-5D literature evidence were gathered (Online Resource 3). The retrieved utilities reflect the valuation of health-related QoL on a scale from zero to one. The retrieved disutilities reflect the valuation of treatment-related complications [46]. Typically, cured PHPT patients will experience a better QoL (mean value of 0.84) [6] than the patients suffering from neurological, cardiovascular, bone or renal events (mean values of 0.59–0.78) [7, 8, 33]. Using these utility values, we calculated the quality-adjusted life years (QALYs) by the discounted sum of utilities over the lifetime evaluation period. According to the Dutch guidelines, an annual discount rate of 1.5% was applied to all future health outcomes [45].

### Base case analysis

Using the cSTM, we calculated the expected health effects and costs of each imaging strategy captured for each treatment setting. We expressed cost-effectiveness in terms of the net monetary benefit (NMB). The NMB was calculated by multiplying the QALYs by the willingness-to-pay (WTP) per QALY and subtracting the costs. The one-stop-shop strategy was considered cost-effective compared to current best practice when the incremental NMB was greater than zero. A WTP value of €50,000 per QALY is recommended by the Dutch healthcare authority for the expected disease burden [45].

### Probabilistic analysis

We conducted a probabilistic analysis applying Monte Carlo experiments to assess joint parameter uncertainty. We randomly sampled 50,000 parameter sets by assigning parametric distributions to all model parameters. Subsequently, both the one-stop-shop strategy and current best practice were evaluated for each parameter set. The point estimates of the cost-effectiveness ratios were plotted in cost-effectiveness planes. The incremental cost-effectiveness ratio (ICER) was the difference in costs divided by the difference in QALYs. As a function of the WTP per QALY, cost-effectiveness acceptability curves (CEACs) were used to visualise the probability that the one-stop-shop strategy was cost-effective compared to current best practice.

### Threshold analysis

We performed two threshold analyses and the results were plotted in decision curves [47]. In the first threshold analysis, we systematically decreased the base case tariff of partial-body [<sup>18</sup>F]FCH PET/CT until the one-stop-shop strategy led to lower costs than current best practice. Tariff estimates ranged from €600 up to €1,445 thereby opting to cover different economic European situations. Tariffs are hospital-specific as tariffs vary between Dutch hospitals ranging from estimates of €754 to €1,307 [48, 49], respectively, country-specific. For example, France handles a degressive pricing system in which tariffs vary between €550–€1,000 per scan depending on the age of the scanner and the annual number of exams performed on that scanner [50]. In the second threshold analysis, we treated the sensitivity of MIBI SPECT/CT as a continuous variable. The expected sensitivity of MIBI SPECT/CT ranged from 60%–90% since the performance of MIBI SPECT/CT is quite uncertain [14–16].



## Sensitivity analysis

To assess the robustness of the model outcomes, we performed a one-way sensitivity analysis with 95% confidence interval ranges for all model parameters compared to the base case. Furthermore, we performed sensitivity analyses in which we changed utility parameter values compared to the base case. First, we assigned a fixed disutility of 0.005 to patients receiving both MIBI SPECT/CT and [ $^{18}\text{F}$ ]FCH PET/CT to account for patient radiation burden [51]. Second, we assigned a fixed disutility of 0.01 to patients receiving three different preoperative scans to account for challenging logistics [11–13], which in turn might result in waiting lists, delayed localisation of the parathyroid adenomas and reduced patient satisfaction.

## Results

### Base case analysis for the ioPTH-monitored treatment setting

The expected total costs per simulated patient in the one-stop-shop strategy were similar to current best practice. The one-stop-shop strategy had an estimated mean total cost of €3,841 per patient and current best practice had an estimated mean total cost of €3,822 per patient. Also, there was no expected clinically relevant difference in the QALYs obtained as the estimated mean total QALY was 12.65 per patient in both strategies. Consequently, the incremental NMB was approximately zero. The results of the Monte Carlo experiments were plotted in cost-effectiveness planes (Online Resource 4, Fig. 1). The results of the adjusted


one-stop-shop strategy including preoperative US were reported in Online Resource 5.

### Base case analysis for the traditional treatment setting

The simulation outcomes of the traditional treatment setting were in line with the ioPTH-monitored treatment setting. The expected total costs per simulated patient in the one-stop-shop strategy were similar to current best practice. The one-stop-shop strategy had an estimated mean total cost of €4,535 per patient and current best practice had an estimated mean total cost of €4,514 per patient. There was no expected clinically relevant difference in the QALYs obtained as the estimated mean total QALY was 12.64 per patient in both strategies. Consequently, the incremental NMB was again approximately zero. The results of the Monte Carlo experiments were plotted in cost-effectiveness planes (Online Resource 4, Fig. 1). The results of the adjusted one-stop-shop strategy including preoperative US were reported in Online Resource 5.

### Threshold analysis

Decision curves show the results of the threshold analyses for the ioPTH-monitored treatment setting. Figure 3a shows that the one-stop-shop strategy was cost-effective when the base case tariff of partial-body [ $^{18}\text{F}$ ]FCH PET/CT (€965) decreased by at least €80 (8.3%) resulting in a suggested tariff of €885. Figure 3b shows that the one-stop-shop strategy was cost-effective when the base case sensitivity of MIBI SPECT/CT (79.6%) decreased to sensitivity values lower than 78%. The results of the threshold analyses for the



**Fig. 3** Decision curves depicting (a) the tariff of [ $^{18}\text{F}$ ]FCH PET/CT on the x-axis and (b) the sensitivity of MIBI SPECT/CT on the x-axis. The total costs including imaging, surgery and pharmacotherapy of the expected PHPT care pathway are depicted on the y-axis and given an ioPTH-monitored treatment setting. Abbreviations:


ioPTH, intraoperative parathyroid hormone serum level. [ $^{18}\text{F}$ ]FCH PET/CT, positron emission tomography and computed tomography using [ $^{18}\text{F}$ ]Fluorocholine. MIBI SPECT/CT, single-photon emission computed tomography and computed tomography using [ $^{99\text{m}}\text{Tc}$ ]Tc-methoxy isobutyl isonitrile. PHPT, primary hyperparathyroidism

traditional treatment setting were similar (Online Resource 4, Fig. 2).

### Sensitivity analysis

A tornado diagram of the one-way sensitivity analysis visualises the input parameters that led to a relative change in the incremental NMB of at least 10% compared to the base case (Online Resource 4, Fig. 3). We observed that the tariff of partial-body [ $^{18}\text{F}$ ]FCH PET/CT had the most impact on the incremental NMB. Furthermore, we applied disutilities to model the health consequences of patient radiation burden and

challenging logistics. The corresponding CEACs were plotted for the ioPTH-monitored treatment setting. If incorporating a disutility for radiation burden, the expected ICER was €48,092 and the probability of the one-stop-shop strategy being cost-effective was 52% at the most accepted WTP threshold of €50,000 per QALY (Fig. 4a). If incorporating a disutility for challenging logistics, the expected ICER was €24,046 and the probability of the one-stop-shop strategy being cost-effective was 66% at the most accepted WTP threshold of €50,000 per QALY (Fig. 4b). The results of sensitivity analyses for the traditional treatment setting were similar (Online Resource 4, Fig. 4).



**Fig. 4** The cost-effectiveness acceptability curves show the probability that the one-stop-shop strategy is cost-effective compared to current best practice at different WTP thresholds per QALY ranging from €0 to €100,000. The first curve (a) shows that incorporating a fixed disutility of 0.005, as a consequence of radiation burden for patients receiving both MIBI SPECT/CT and [ $^{18}\text{F}$ ]FCH PET/CT, results in an ICER of €48,092 and a 52% probability that the one-stop-shop strategy is cost-effective at the most accepted WTP threshold of €50,000 per QALY. The second curve (b) shows that incorporating a fixed disutility of 0.01, as a consequence of challenging

logistics for patients receiving three different preoperative scans, results in an ICER of €24,046 and a 66% probability that the one-stop-shop strategy is cost-effective at the most accepted WTP threshold of €50,000 per QALY. Abbreviations: WTP, willingness-to-pay. QALY, quality-adjusted life year. ICER, incremental cost-effectiveness ratio. [ $^{18}\text{F}$ ]FCH PET/CT, positron emission tomography and computed tomography using [ $^{18}\text{F}$ ]Fluorocholine. MIBI SPECT/CT, single-photon emission computed tomography and computed tomography using [ $^{99\text{m}}\text{Tc}$ ]Tc-methoxy isobutyl isonitrite



## Discussion

This study explored the cost-effectiveness of two imaging strategies to localise parathyroid adenomas and to guide succeeding treatment for patients suffering from PHPT: the [ $^{18}\text{F}$ ]FCH PET/CT-based one-stop-shop strategy and current best practice in which [ $^{18}\text{F}$ ]FCH PET/CT is only recommended after negative or inconclusive MIBI SPECT/CT. The simulated health effects and costs were similar for both imaging strategies. Accordingly, the one-stop-shop strategy is not associated with lower costs and both imaging strategies can be used interchangeably. This applies to both the ioPTH-monitored treatment setting in which MIP might immediately be converted to explorative neck dissection as well as the traditional treatment setting in which ioPTH is not monitored. The total PHPT care pathway costs, however, varied between the ioPTH-monitored and traditional treatment setting (estimated values of €3,822–€3,841 compared to €4,514–€4,535). A recent Cochrane review discussed that there exists considerable uncertainty surrounding such estimates which might be explained by differences in hospital charges for surgical procedures as well as differences in the surgical protocols [26].

In essence, the decision to implement either imaging strategy depends on available local resources as well as patient preferences. We want to emphasise that daily clinical practice grounds – such as easy resource capacity allocation, reduced waiting times, reduced travel times, reduced hospital waste, reduced patient radiation burden and meeting patient preferences – should inform the policy-making on whether a hospital should implement the one-stop-shop imaging strategy. The one-stop-shop strategy decreases the number of hospital visits which is fundamentally preferable in terms of logistics, environmental impact and interference in patients' lives. Also, the one-stop-shop strategy is preferred when healthcare resources are limited as it has a lower impact on scarce resources. Moreover, the one-stop-shop strategy might save approximately half the radiation burden of current best practice. Of course, the availability of [ $^{18}\text{F}$ ]FCH PET/CT scanners, radiopharmaceuticals and personnel should be taken into consideration when opting for the one-stop-shop strategy.

In current practice, preoperative cervical US is used to rule out thyroid disorders [9]. Nevertheless, a strategy including US and [ $^{18}\text{F}$ ]FCH PET/CT but without MIBI SPECT/CT might not be considered a relevant strategy for cost-effectiveness analysis. Most importantly, because [ $^{18}\text{F}$ ]FCH PET/CT allows for MIP, therefore, trauma after surgery is generally minimal and does not lead to additional risks if re-intervention in the neck region (for thyroid disease) would be necessary. Second, because [ $^{18}\text{F}$ ]FCH PET/CT has a very high negative predictive value

to rule out thyroid cancer [52], and the low-dose CT performed during [ $^{18}\text{F}$ ]FCH PET/CT may not be suitable to exclude coincidental thyroid carcinoma but provides the surgeon with anatomical context in case of thyroid nodules or goitre. If the local situation does not allow omitting US, costs will increase approximately at the rate of preoperative US but a clinically relevant increase in QALYs may not be expected (Online Resource 5).

To our knowledge, only one study assessed the cost-effectiveness of [ $^{18}\text{F}$ ]FCH PET/CT regarding the localisation of enlarged parathyroids [53]. The authors argued that [ $^{18}\text{F}$ ]FCH PET/CT is potentially a cost-effective imaging technique in the United States. They, however, performed a head-to-head comparison of [ $^{18}\text{F}$ ]FCH PET/CT with stand-alone conventional imaging including 4-dimensional CT, US, and MIBI SPECT, while we compared an [ $^{18}\text{F}$ ]FCH PET/CT-based one-stop-shop strategy with the use of [ $^{18}\text{F}$ ]FCH PET/CT after negative or inconclusive conventional imaging including sequential US and MIBI SPECT/CT. Where models focus on stand-alone imaging without consideration of sequential imaging, there is a profound source of structural uncertainty implying that the cost-effectiveness of imaging across the PHPT care pathway remains uncertain [54–56].

The American study reported substantial incremental QALY benefits (values of 0.02–0.05) [53], whereas we could not find such QALY benefits. The American study also reported relatively high cost outcomes (values approximating €10,000) [53], whereas we found at most half these costs. These differences might be explained by the modelling methods used in combination with the different tariffs of imaging, surgery and pharmacotherapy within the American and European healthcare systems. The choice of modelling method depends on the complexity of the clinical process to be modelled, the available evidence and the modellers' experience. We obtained all model parameter values from aggregated literature evidence complemented with expert elicitation, justifying that we developed a cSTM.

This study has some limitations. We simulated imaging test results using conditional probabilities reflecting the diagnostic performance of MIBI SPECT/CT and [ $^{18}\text{F}$ ]FCH PET/CT. The performance of [ $^{18}\text{F}$ ]FCH PET/CT, however, varies between current best practice and the one-stop-shop strategy because [ $^{18}\text{F}$ ]FCH PET/CT can be used as first-line or second-line imaging. Where there was abundant evidence available to properly estimate the performance of [ $^{18}\text{F}$ ]FCH PET/CT as second-line imaging (base case accuracy of 76% used for simulations [11–13]), limited evidence was available of [ $^{18}\text{F}$ ]FCH PET/CT as first-line imaging (base case accuracy of 96% used for simulations [14–16]). Nonetheless, [ $^{18}\text{F}$ ]FCH PET/CT would be the most favourable imaging technique for the localisation of parathyroid adenomas and its superior performance has been demonstrated in several reviews and meta-analyses [19, 57–61]. Sequentially, patient

outcomes can be improved with effective patient management after localisation with imaging. Further patient management depends on contextual factors within the treatment pathway including the availability of surgical and pharmacological procedures and their effectiveness. Therefore, assessing the clinical utility of imaging requires an integrated approach that considers all contextual factors along the treatment pathway.

Also, the time to repeat imaging may impact clinical utility. The simulated time to repeat imaging was based on expert judgements assuming a constant exponential hazard rate as we tend to decrease imaging frequency once the previous imaging results were negative. We validated whether this assumption was accurate with extreme parameter value testing, testing of traces in which patients were tracked through the model, and unit testing in which sub-modules of the model were tested. The time to repeat imaging was found to be comparable with published EUROCRINE evidence [37].

It is noteworthy that the clinical utility of imaging might be estimated in randomised controlled trials. However, trials are not always recommended since they are costly and time-consuming. They are also considered less feasible given all combinations of imaging and therapeutics that can be compared in this setting. Moreover, trials do often not allow assessment of lifetime outcomes or risks related to imaging (e.g., patient radiation burden due to imaging). Model-based cost-effectiveness analysis should be seen as a valid alternative [62]. However, cost-effectiveness models evaluating imaging will be more complex and require more evidence than models evaluating therapeutics. Given the complexity and dependencies related to the use of imaging, researchers may not always be fully aware of all the different aspects potentially influencing the results of a model-based cost-effectiveness study, and the results of model-based cost-effectiveness studies are only relevant insofar as they represent current clinical practice in the specific decision context [63].

The results of this study can be used to revise international guidelines for parathyroid imaging [9, 10]. The need for revision is underpinned by previous studies showing that there exists a substantial variation in the imaging tests used [17, 18]. Additional studies, preferably based on data from randomised clinical trials and analysing clinical patterns across multiple lines of sequential imaging rather than stand-alone imaging, are required to reach a comprehensive evidence base for guideline improvement. The inclusion of cost-effectiveness studies in the guideline revision process will lead to a more sensible use of scarce healthcare resources.

This study represents the first cost-effectiveness analysis encompassing sequential imaging, surgery and pharmacotherapy. We demonstrated that the one-stop-shop imaging

strategy can be seamlessly integrated into routine clinical practice with negligible additional expenses for hospitals. Therefore, the adoption of the one-stop-shop strategy hinges primarily on the availability of local resources.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00259-024-06771-1>.

**Acknowledgements** This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector. Acknowledgements: none to declare.

**Author contributions** All authors contributed to the study's conception and design. Material preparation, data collection and analysis were performed by Sietse van Mossel. The first draft of the manuscript was written by Sietse van Mossel and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding** The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

**Data Availability** The datasets generated and/or analysed during the current study are available in the Supplementary Information. Software codes on which the conclusions of our paper rely are available upon reasonable substantiated request.

## Declarations

**Ethics approval** This study was exempt from approval by the local ethics committee as it did not include patient data. Instead, all model parameters were obtained from literature evidence or were elicited from an expert panel. No ethical approval was required.

**Competing interests** The authors have no relevant financial or non-financial interests to disclose.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Bilezikian JP, Cusano NE, Khan AA, Liu J-M, Marcocci C, Bandeira F. Primary hyperparathyroidism. *Nat Rev Dis Primers*. 2016;2:1–16.
2. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. *Lancet*. 2018;391:168–78.
3. Walker MD, Silverberg SJ. Primary hyperparathyroidism. *Nat Rev Endocrinol*. 2018;14:115–25.
4. Fraser WD. Hyperparathyroidism. *Lancet*. 2009;374:145–58.
5. Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, et al. Morphometric vertebral fractures in

- postmenopausal women with primary hyperparathyroidism. *J Clin Endocrinol Metab.* 2009;94:2306–12.
6. Ye Z, Silverberg SJ, Sreekanta A, Tong K, Wang Y, Chang Y, et al. The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials. *J Bone Miner Res.* 2022;37:2351–72.
  7. Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis JA, Kellingray S, Leplege A, Liberman UA, McCloskey E, Minne H, Reeve J, Reginster JY, Scholz M, Todd C, de Vernejoul MC, Wiklund I. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. *Osteoporos Int.* 1999;10(2):150–60. <https://doi.org/10.1007/s001980050210>.
  8. Tapiero S, Limfucio L, Bechis SK, Sur RL, Penniston KL, Nakada SY, et al. The impact of the number of lifetime stone events on quality of life: results from the North American stone quality of life consortium. *Urolithiasis.* 2021;49:321–6.
  9. Ovčariček PP, Giovanella L, Gasset IC, Hindié E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. *Eur J Nucl Med Mol Imaging.* 2021;48:2801–22.
  10. Hindié E, Ugur Ö, Fuster D, O'Doherty M, Grassetto G, Ureña P, et al. 2009 EANM parathyroid guidelines. *Eur J Nucl Med Mol Imaging.* 2009;36:1201–16.
  11. Kluijfhout WP, Vorselaars WCM, Van Den Berk SAM, Vriens MR, Borel Rinkes IHM, Valk GD, et al. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. *Nucl Med Commun.* 2016;37:1246–52.
  12. Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. *Eur J Nucl Med Mol Imaging.* 2018;45:658–66.
  13. Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, et al. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. *Eur J Nucl Med Mol Imaging.* 2018;45:1772–80.
  14. Broos WAM, Wondergem M, Knol RJJ, van der Zant FM. Parathyroid imaging with 18F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study. *EJNMMI Res.* 2019;9:72.
  15. Beheshti M, Hehenwarter L, Paymani Z, Rendl G, Imamovic L, Rettenbacher R, et al. 18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. *Eur J Nucl Med Mol Imaging.* 2018;45:1762–71.
  16. Cuderman A, Senica K, Rep S, Hocevar M, Kocjan T, Sever MJ, et al. 18F-fluorocholine PET/CT in primary hyperparathyroidism: Superior diagnostic performance to conventional scintigraphic imaging for localization of hyperfunctioning parathyroid glands. *J Nucl Med.* 2020;61:577–83.
  17. Hindi E, Schwartz P, Avram AM, Imperiale A, Sebag F, Taïeb D. Primary Hyperparathyroidism: defining the appropriate preoperative imaging algorithm. *J Nucl Med.* 2021;62:3–12.
  18. Giovanella L, Bacigalupo L, Treglia G, Piccardo A. Will 18 F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging? *Endocrine.* 2020;71:285–97.
  19. Lee SW, Shim SR, Jeong SY, Kim SJ. Direct comparison of preoperative imaging modalities for localization of primary hyperparathyroidism: a systematic review and network meta-analysis. *JAMA Otolaryngol-Head Neck Surg.* 2021;147:692–706.
  20. Udelsman R, Åkerström G, Biagini C, Duh Q-Y, Miccoli P, Niederle B, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. *J Clin Endocrinol Metab.* 2014;99:3595–606.
  21. Kunstman JW, Kirsch JD, Mahajan A, Udelsman R. Parathyroid localization and implications for clinical management. *J Clin Endocrinol Metab.* 2013;98:902–12.
  22. Callender GG, Udelsman R. Surgery for primary hyperparathyroidism. *Cancer.* 2014;120:3602–16.
  23. Stephen AE, Mannstadt M, Hodin RA. Indications for surgical management of hyperparathyroidism: a review. *JAMA Surg.* 2017;152:878–82.
  24. Bilezikian JP, Silverberg SJ, Bandeira F, Cetani F, Chandran M, Cusano NE, et al. Management of primary hyperparathyroidism. *J Bone Miner Res.* 2022;37:2391–403.
  25. Bergenfelz A, Van Slycke S, Makay Ö, Brunaud L. European multicentre study on outcome of surgery for sporadic primary hyperparathyroidism. *Br J Surg.* 2021;108:675–83.
  26. Ahmadiéh H, Kreidieh O, Akl EA, El-Hajj FG. Minimally invasive parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IOPH) and preoperative imaging versus bilateral neck exploration for primary hyperparathyroidism in adults. *Cochrane Database Syst Rev.* 2020;10:1465–858.
  27. Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. *Ann Surg.* 2011;253:585–91.
  28. Schneider DF, Mazeh H, Sippel RS, Chen H. Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases. *Surgery.* 2012;152:1008–15.
  29. Schneider DF, Mazeh H, Chen H, Sippel RS. Predictors of recurrence in primary hyperparathyroidism: an analysis of 1386 cases. *Ann Surg.* 2014;259:563–8.
  30. Smit PC, Rinkes IHMB, Van Dalen A, Van Vroonhoven TJMV. Direct, minimally invasive adenomectomy for primary hyperparathyroidism: an alternative to conventional neck exploration? *Ann Surg.* 2000;231:559–65.
  31. Westerdahl J, Bergenfelz A. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial. *Ann Surg.* 2007;246:976–80.
  32. Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. *Ann Surg.* 2002;236:543–51.
  33. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. *J Bone Miner Res.* 2013;28:2277–85.
  34. Hadker N, Egan J, Sanders J, Lagast H, Clarke BL. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the paradox study. *Endocr Pract.* 2014;20:671–9.
  35. Astor MC, Løvas K, Debowska A, Eriksen EF, Evang JA, Fossum C, et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. *J Clin Endocrinol Metab.* 2016;101:3045–53.
  36. Vokes T. Quality of life in hypoparathyroidism. *Bone.* 2019;120:542–7.
  37. Eurocrine. European Registry for Endocrine Surgery. <https://eurocrine.eu/about-eurocrine>. Accessed February 5, 2024.
  38. R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>.

39. Alarid-Escudero F, Knowlton G, Easterly C, Enns EA. Decision Analytic Modeling Package (dampack). R package version 1.0.0; 2021. <https://github.com/DARTH-git/dampack>.
40. Alarid-Escudero F, Krijkamp E, Pechlivanoglou P, Jalal H, Yang A, Enns E. `_darthtools`: `darthtools` is an R package that contains tools developed by the Decision Analysis in R for Technologies in Health (DARTH) workgroup to construct model-based cost-effectiveness analysis in R.; 2024. <https://darth-git.github.io/darthtools>, <https://github.com/DARTH-git/darthtools>.
41. Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. *BMJ*. 2022;376:e067975.
42. Centraal bureau voor statistiek (CBS). StatLine - Levensverwachting; geslacht, leeftijd. <https://opendata.cbs.nl/statline/#/CBS/nl/dataset/37360ned/table?dl=4CA57>. Accessed February 5. 2024.
43. Dutch Healthcare Authority. Dutch dbc-information system. <https://www.opendisdata.nl>. Accessed August 25. 2023.
44. Dutch Healthcare authority. Dutch drug database. <https://www.medicijnkosten.nl>. Accessed August 25. 2023.
45. Dutch Healthcare Authority. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. <https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg>. Accessed February 5. 2024.
46. Versteegh M, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA. Dutch Tariff for the Five-Level Version of EQ-5D. *Value Health*. 2016;19:343–52.
47. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. *Diagn Progn Res*. 2019;3:18.
48. de Koster EJ, Vriens D, van Aken MO, Dijkhorst-Oei LT, Oyen WJG, Peeters RP, et al. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. *Eur J Nucl Med Mol Imaging*. 2022;49:3452–69.
49. Greuter MJE, Eertink JJ, Jongeneel G, Dührsen U, Hüttmann A, Schmitz C, et al. Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. *Clin Lymphoma Myeloma Leuk*. 2022;22:382–92.
50. Ministère des affaires sociales et de la santé. Décrets, arrêtés, circulaires textes généraux. <https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000034026295>. Accessed February 5. 2024.
51. Cipriano LE, Levesque BG, Zaric GS, Loftus EV, Sandborn WJ. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. *Inflamm Bowel Dis*. 2012;18:1240–8.
52. Ciappuccini R, Licaj I, Lasne-Cardon A, Babin E, De Raucourt D, Blanchard D, et al. 18F-fluorocholine positron emission tomography/computed tomography is a highly sensitive but poorly specific tool for identifying malignancy in thyroid nodules with indeterminate cytology: the chocolate study. *Thyroid*. 2021;31:800–9.
53. Yap A, Hope TA, Graves CE, Kluijfhout W, Shen WT, Gosnell JE, et al. A cost-utility analysis of 18F-fluorocholine-positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. *Surgery*. 2022;171:55–62.
54. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. *Med Decis Making*. 2012;32:678–89.
55. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices-overview: a report of the ISPOR-SMDM modeling good research practices task force-1. *Med Decis Making*. 2012;32:667–77.
56. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. *Pharmacoeconomics*. 2006;24(4):355–71. <https://doi.org/10.2165/00019053-200624040-00006>.
57. Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, et al. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging*. 2019;46:751–65.
58. Evangelista L, Ravelli I, Magnani F, Iacobone M, Giraudo C, Camozzi V, et al. 18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature. *Ann Nucl Med*. 2020;34:601–19.
59. Broos WAM, Van Der Zant FM, Knol RJJ, Wondergem M. Choline PET/CT in parathyroid imaging: a systematic review. *Nucl Med Commun*. 2019;40:96–105.
60. Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. *Langenbecks Arch Surg*. 2016;401:925–35.
61. Whitman J, Allen IE, Bergsland EK, Suh I, Hope TA. Assessment and comparison of 18F-Fluorocholine PET and 99mTc-sestamibi scans in identifying parathyroid adenomas: a metaanalysis. *J Nucl Med*. 2021;62:1285–91.
62. Koffijberg H, van Zaane B, Moons KG. From accuracy to patient outcome and cost-effectiveness evaluations of diagnostic tests and biomarkers: an exemplary modelling study. *BMC Med Res Methodol*. 2013;13:12. <https://doi.org/10.1186/1471-2288-13-12>.
63. Langer A. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? *BMC Health Serv Res*. 2010;10:283. <https://doi.org/10.1186/1472-6963-10-283>.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.